JP2007314577A - ナトリウム/プロトン交換体(nhe)の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のnhe阻害効果を評価する方法 - Google Patents
ナトリウム/プロトン交換体(nhe)の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のnhe阻害効果を評価する方法 Download PDFInfo
- Publication number
- JP2007314577A JP2007314577A JP2007223309A JP2007223309A JP2007314577A JP 2007314577 A JP2007314577 A JP 2007314577A JP 2007223309 A JP2007223309 A JP 2007223309A JP 2007223309 A JP2007223309 A JP 2007223309A JP 2007314577 A JP2007314577 A JP 2007314577A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- inhibitors
- pharmaceutically acceptable
- nhe
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC(C)C(CC[C@](C)[C@@](CC1)C2(C)C1C1[C@@](*)CC(CCCC3)C3(C)C1CC2)*=C Chemical compound CC(C)C(CC[C@](C)[C@@](CC1)C2(C)C1C1[C@@](*)CC(CCCC3)C3(C)C1CC2)*=C 0.000 description 6
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Neurology (AREA)
Abstract
【解決手段】NHEの阻害剤として有用な、化合物FX1A、化合物FX1B、化合物1360、化合物1361、化合物371、化合物1437および化合物353などの、新規に単離および合成されたアミノステロール化合物またはその薬学的に許容される塩であって、これらのステロイド化合物の中には、種々のNHEを阻害することが見出されているものもあれば、単一の特定のNHEを有利に阻害することが見出されているものもあり、これらの化合物の構造は、本明細書に示されるとおりである。
【選択図】なし
Description
Claims (8)
- 糖尿病の処置のための薬剤を製造するための、化合物の使用であって、ここで、該化合物は:
以下の構造
以下の構造
以下の構造
以下の構造
以下の構造
以下の構造
以下の構造
を有する化合物、
からなる群から選択される化合物である、使用。 - NHEを阻害するため組成物であって、ここで、NHEの阻害は糖尿病の処置を提供するのに有用であり、ここで該組成物は:
以下の構造
以下の構造
以下の構造
以下の構造
以下の構造
以下の構造
以下の構造
を有する化合物、
からなる群から選択される化合物を含有する、組成物。 - 脊椎動物の直線的成長を抑制するための薬剤を製造するための化合物の使用であって、ここで、該化合物は、以下の構造
- 脊椎動物の体重増加を抑制するための薬剤を製造するための化合物の使用であって、ここで、該化合物は、以下の構造
- 脊椎動物の直線的成長を抑制するための組成物であって、ここで、該組成物は、以下の構造
- 脊椎動物の体重増加を抑制するための組成物であって、ここで、該組成物は、以下の構造
- 脊椎動物の体重減少を誘導するための薬剤を製造するための化合物の使用であって、ここで、該化合物は、以下の構造
- 脊椎動物の体重減少を誘導するため組成物であって、ここで、該組成物は、以下の構造
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/479,455 | 1995-06-07 | ||
US08/483,059 US5840740A (en) | 1995-06-07 | 1995-06-07 | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
US08/475,572 | 1995-06-07 | ||
US08/476,855 US5874597A (en) | 1995-06-07 | 1995-06-07 | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US08/487,443 | 1995-06-07 | ||
US08/483,057 US5795885A (en) | 1995-06-07 | 1995-06-07 | Method of inhibiting profileration of cells by administering an aminosterol compound |
US08/475,572 US5840936A (en) | 1995-06-07 | 1995-06-07 | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
US08/483,057 | 1995-06-07 | ||
US08/487,443 US5847172A (en) | 1995-06-07 | 1995-06-07 | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US08/476,855 | 1995-06-07 | ||
US08/479,457 US5763430A (en) | 1995-06-07 | 1995-06-07 | Method of treating a viral infection by administering a steroid compound |
US08/479,457 | 1995-06-07 | ||
US08/479,455 US5994336A (en) | 1995-06-07 | 1995-06-07 | Method of inhibiting proliferation of cells by administering an aminosterol compound |
US08/483,059 | 1995-06-07 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50230797A Division JP4104164B2 (ja) | 1995-06-07 | 1996-06-07 | ナトリウム/プロトン交換体(nhe)の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のnhe阻害効果を評価する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007314577A true JP2007314577A (ja) | 2007-12-06 |
JP2007314577A6 JP2007314577A6 (ja) | 2008-03-13 |
Family
ID=27569803
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50230797A Expired - Lifetime JP4104164B2 (ja) | 1995-06-07 | 1996-06-07 | ナトリウム/プロトン交換体(nhe)の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のnhe阻害効果を評価する方法 |
JP2007223309A Withdrawn JP2007314577A (ja) | 1995-06-07 | 2007-08-29 | ナトリウム/プロトン交換体(nhe)の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のnhe阻害効果を評価する方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50230797A Expired - Lifetime JP4104164B2 (ja) | 1995-06-07 | 1996-06-07 | ナトリウム/プロトン交換体(nhe)の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のnhe阻害効果を評価する方法 |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP0832094B1 (ja) |
JP (2) | JP4104164B2 (ja) |
AT (1) | ATE259375T1 (ja) |
AU (1) | AU723663C (ja) |
CA (1) | CA2223910C (ja) |
DE (1) | DE69631527T2 (ja) |
DK (1) | DK0832094T3 (ja) |
ES (1) | ES2216049T3 (ja) |
PT (1) | PT832094E (ja) |
WO (1) | WO1996040728A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011519877A (ja) * | 2008-05-09 | 2011-07-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856535A (en) * | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
US6143738A (en) * | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
PT910382E (pt) * | 1996-04-26 | 2003-10-31 | Genaera Corp | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores |
US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
EP0923377A1 (en) * | 1996-05-17 | 1999-06-23 | Magainin Pharmaceuticals Inc. | Therapeutic uses for an aminosterol compound |
US7410959B1 (en) | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
WO1998019682A1 (en) * | 1996-11-01 | 1998-05-14 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and uses therefor |
US6262283B1 (en) | 1996-12-06 | 2001-07-17 | Magainin Pharmaceuticals Inc. | Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds |
DE19737463A1 (de) * | 1997-08-28 | 1999-03-04 | Hoechst Marion Roussel De Gmbh | Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden |
DE60123939T2 (de) | 2000-04-12 | 2007-05-31 | Genaera Corp. | Ein verfahren zur herstellung von 7.alpha.-hydroxy 3-aminosubstituierten sterol-verbindungen, ohne schutz der 7.alpha.-hydroxy-gruppe |
WO2006119211A2 (en) * | 2005-05-02 | 2006-11-09 | Genaera Corporation | Methods and compositions for treating ocular disorders |
US20080058300A1 (en) * | 2006-04-21 | 2008-03-06 | Mclane Michael | Induction of weight loss and the selective inhibition of PTP1B |
CA2697744C (en) * | 2007-09-06 | 2016-06-14 | Genaera Corporation | A method for treating diabetes |
CN103957919B (zh) * | 2011-09-19 | 2018-10-16 | 瑞士苏黎世联邦理工学院 | RORγ调节剂 |
KR101963312B1 (ko) * | 2012-04-20 | 2019-03-28 | 오에이치알 파마서티컬, 인코포레이티드 | Ptp1b 연관 질병의 치료용 아미노스테로이드 |
CN110420211A (zh) | 2013-03-15 | 2019-11-08 | 布莱阿姆青年大学 | 治疗炎症、自身免疫性疾病和疼痛的方法 |
US11524015B2 (en) | 2013-03-15 | 2022-12-13 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
EP2781217A1 (en) * | 2013-03-18 | 2014-09-24 | ETH Zurich | ROR gamma modulators |
US10040817B2 (en) * | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
US11690855B2 (en) | 2013-10-17 | 2023-07-04 | Brigham Young University | Methods for treating lung infections and inflammation |
US20150203527A1 (en) | 2014-01-23 | 2015-07-23 | Brigham Young University | Cationic steroidal antimicrobials |
US10441595B2 (en) * | 2014-06-26 | 2019-10-15 | Brigham Young University | Methods for treating fungal infections |
FR3033563B1 (fr) * | 2015-03-12 | 2018-04-13 | Virbac | Composes analogues de la squalamine utiles comme agents antibacteriens |
FR3055801B1 (fr) * | 2016-09-15 | 2020-10-30 | Virbac | Derives esters de squalamine pour le traitement des infections |
EP3678671A4 (en) | 2017-09-08 | 2022-12-07 | Enterin, Inc. | METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS |
US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
WO2020028810A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Compositions and methods for treating brain-gut disorders |
CN112782300B (zh) * | 2020-12-25 | 2022-04-12 | 山东省食品药品检验研究院 | 一种胆烷酸的同分异构体及其检测方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192756A (en) * | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6392894A (en) * | 1993-02-26 | 1994-09-14 | Magainin Pharmaceuticals, Inc. | Chemical synthesis of squalamine |
ES2123133T3 (es) * | 1993-03-10 | 1999-01-01 | Magainin Pharma | Derivados esteroidianos, composiciones farmaceuticas que contienen estos derivados esteroidianos y utilizacion de estos ultimos como antibioticos o desinfectantes. |
-
1996
- 1996-06-07 EP EP96922490A patent/EP0832094B1/en not_active Expired - Lifetime
- 1996-06-07 CA CA002223910A patent/CA2223910C/en not_active Expired - Lifetime
- 1996-06-07 AU AU63349/96A patent/AU723663C/en not_active Ceased
- 1996-06-07 EP EP04002943A patent/EP1420027A3/en not_active Withdrawn
- 1996-06-07 DE DE69631527T patent/DE69631527T2/de not_active Expired - Lifetime
- 1996-06-07 DK DK96922490T patent/DK0832094T3/da active
- 1996-06-07 PT PT96922490T patent/PT832094E/pt unknown
- 1996-06-07 JP JP50230797A patent/JP4104164B2/ja not_active Expired - Lifetime
- 1996-06-07 ES ES96922490T patent/ES2216049T3/es not_active Expired - Lifetime
- 1996-06-07 AT AT96922490T patent/ATE259375T1/de not_active IP Right Cessation
- 1996-06-07 WO PCT/US1996/010508 patent/WO1996040728A2/en active IP Right Grant
-
2007
- 2007-08-29 JP JP2007223309A patent/JP2007314577A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192756A (en) * | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011519877A (ja) * | 2008-05-09 | 2011-07-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物 |
US10292949B2 (en) | 2008-05-09 | 2019-05-21 | Meck Patent Gmbh | Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and β-cell dysfunction |
Also Published As
Publication number | Publication date |
---|---|
CA2223910C (en) | 2008-09-16 |
AU723663C (en) | 2001-11-01 |
EP1420027A2 (en) | 2004-05-19 |
EP0832094A2 (en) | 1998-04-01 |
EP1420027A3 (en) | 2012-01-04 |
DK0832094T3 (da) | 2004-05-17 |
PT832094E (pt) | 2004-06-30 |
JP4104164B2 (ja) | 2008-06-18 |
EP0832094B1 (en) | 2004-02-11 |
ATE259375T1 (de) | 2004-02-15 |
WO1996040728A2 (en) | 1996-12-19 |
DE69631527D1 (de) | 2004-03-18 |
AU6334996A (en) | 1996-12-30 |
AU723663B2 (en) | 2000-08-31 |
JP2002515019A (ja) | 2002-05-21 |
DE69631527T2 (de) | 2004-09-23 |
ES2216049T3 (es) | 2004-10-16 |
WO1996040728A3 (en) | 1997-03-27 |
CA2223910A1 (en) | 1996-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007314577A (ja) | ナトリウム/プロトン交換体(nhe)の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のnhe阻害効果を評価する方法 | |
JP2007314577A6 (ja) | ナトリウム/プロトン交換体(nhe)の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のnhe阻害効果を評価する方法 | |
JP5926731B2 (ja) | 変異cftrタンパク質の修飾因子としての化合物及びcftrタンパク質異常に関連する病気の治療へのその使用 | |
DE502005002596D1 (de) | Pulver enthaltend neuartige oligosaccharidgemische und verfahren zu deren herstellung | |
JPS62500871A (ja) | 薬理活性を有するジペプチド化合物及びそれを含む組成物 | |
HUP0104666A2 (hu) | Új tiroid receptor ligandumok és II-es módszer | |
Powell et al. | Therapeutic approaches to repair defects in ΔF508 CFTR folding and cellular targeting | |
DK1487829T3 (da) | Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte | |
TW201619142A (zh) | 利用替唑尼特(tizoxanide)、其類似物或鹽類之前驅藥的組成物及治療方法 | |
US20030125380A1 (en) | Tricyclic rantes receptor ligands | |
CN107973834A (zh) | 作为fxr/tgr5调节剂的胆酸衍生物 | |
EP2279750A1 (en) | Aniline derivative having anti-rna viral activity | |
CN110035745A (zh) | 小分子ampk活化剂 | |
EP2637644A1 (de) | Lisurid, tergurid und derivate davon zur verwendung in der prophylaxe und/oder therapie fibrotischer veränderungen | |
SA05260130B1 (ar) | تركيب صيدلي مضاد للميكروبات البكتيرية antimycobacterial متضمن عقار ضد التدرن الرئوي (السل) antituvercular | |
KR950018037A (ko) | 시알산 유도체 | |
Cattaneo‐Pangrazzi et al. | The novel heterodinucleoside dimer 5‐FdU‐NOAC is a potent cytotoxic drug and a p53‐independent inducer of apoptosis in the androgen‐independent human prostate cancer cell lines PC‐3 and DU‐145 | |
FR2690847B1 (fr) | Compositions a activite agoniste des recepteurs analogues a 5ht1 selective. | |
WO2017174879A1 (en) | Compounds for use in the treatment of cancer | |
JPH0352816A (ja) | 腎炎の治療剤 | |
HUP0401967A2 (hu) | Nikotinsav-acetilkolin-receptor-agonisták alkalmazása nyugtalan láb szindróma kezelésére alkalmas gyógyszerkészítmények előállítására | |
JP7224303B2 (ja) | 薬剤、組成物、及びそれに関連する方法 | |
US20050119197A1 (en) | Naadp analogues for modulating t-cell activity | |
JPS6239522A (ja) | 酵素阻害剤 | |
EP0120019A1 (de) | Pharmazeutische zubereitungen mit zytostatischer wirkung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070829 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101005 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101228 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110106 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110207 |